Immunic Analyst Ratings
Immunic Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/27/2023 | 129.36% | Wedbush | → $5 | Reiterates | Outperform → Outperform |
| 01/31/2023 | 129.36% | Wedbush | → $5 | Assumes | → Outperform |
| 10/21/2022 | 129.36% | SVB Leerink | $9 → $5 | Downgrades | Outperform → Market Perform |
| 09/19/2022 | 1092.66% | HC Wainwright & Co. | → $26 | Assumes | → Buy |
| 08/08/2022 | 1505.5% | Aegis Capital | $40 → $35 | Maintains | Buy |
| 06/03/2022 | 312.84% | SVB Leerink | $45 → $9 | Maintains | Outperform |
| 05/18/2022 | 1688.99% | Piper Sandler | $71 → $39 | Maintains | Overweight |
| 09/07/2021 | 1046.79% | HC Wainwright & Co. | $40 → $25 | Maintains | Buy |
| 04/15/2021 | 2422.94% | Aegis Capital | → $55 | Initiates Coverage On | → Buy |
| 03/24/2021 | 2422.94% | JMP Securities | → $55 | Initiates Coverage On | → Market Outperform |
| 10/02/2020 | 1964.22% | SVB Leerink | → $45 | Initiates Coverage On | → Outperform |
| 08/26/2020 | 3156.88% | Piper Sandler | → $71 | Initiates Coverage On | → Overweight |
| 08/21/2020 | 2468.81% | HC Wainwright & Co. | $60 → $56 | Maintains | Buy |
| 08/03/2020 | 2652.29% | HC Wainwright & Co. | $45 → $60 | Maintains | Buy |
| 07/20/2020 | 1734.86% | BMO Capital | → $40 | Initiates Coverage On | → Outperform |
| 06/05/2020 | 2606.42% | Wedbush | → $59 | Initiates Coverage On | → Outperform |
| 05/11/2020 | 1964.22% | HC Wainwright & Co. | → $45 | Initiates Coverage On | → Buy |
| 08/12/2019 | 1734.86% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 07/11/2019 | 1734.86% | Chardan Capital | → $40 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 07/27/2023 | 129.36% | Wedbush | → 5 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 01/31/2023 | 129.36% | Wedbush | → 5 美元 | 假設 | → 跑贏大盤 |
| 2022 年 10 月 21 日 | 129.36% | SVB Leerink | 9 美元 → 5 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 09/19/2022 | 1092.66% | HC Wainwright & Co. | → 26 美元 | 假設 | → 購買 |
| 08/08/2022 | 1505.5% | 宙斯盾資本 | 40 美元 → 35 美元 | 維護 | 購買 |
| 06/03/2022 | 312.84% | SVB Leerink | 45 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 05/18/2022 | 1688.99% | 派珀·桑德勒 | 71 美元 → 39 美元 | 維護 | 超重 |
| 09/07/2021 | 1046.79% | HC Wainwright & Co. | 40 美元 → 25 美元 | 維護 | 購買 |
| 2021 年 4 月 15 日 | 2422.94% | 宙斯盾資本 | → 55 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 3 月 24 日 | 2422.94% | JMP 證券 | → 55 美元 | 啓動覆蓋開啓 | → 市場跑贏大盤 |
| 2020 年 2 月 10 日 | 1964.22% | SVB Leerink | → 45 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/26/2020 | 3156.88% | 派珀·桑德勒 | → 71 美元 | 啓動覆蓋開啓 | → 超重 |
| 08/21/2020 | 2468.81% | HC Wainwright & Co. | 60 美元 → 56 美元 | 維護 | 購買 |
| 2020 年 3 月 8 日 | 2652.29% | HC Wainwright & Co. | 45 美元 → 60 美元 | 維護 | 購買 |
| 2020 年 7 月 20 日 | 1734.86% | BMO 資本 | → 40 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2020 年 5 月 6 日 | 2606.42% | Wedbush | → 59 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 05/11/2020 | 1964.22% | HC Wainwright & Co. | → 45 美元 | 啓動覆蓋開啓 | → 購買 |
| 08/12/2019 | 1734.86% | 查丹資本 | → 40 美元 | 啓動覆蓋開啓 | → 購買 |
| 2019 年 11 月 7 日 | 1734.86% | 查丹資本 | → 40 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for Immunic (IMUX)?
Immunic (IMUX) 的目標價格是多少？
The latest price target for Immunic (NASDAQ: IMUX) was reported by Wedbush on July 27, 2023. The analyst firm set a price target for $5.00 expecting IMUX to rise to within 12 months (a possible 129.36% upside). 5 analyst firms have reported ratings in the last year.
Wedbush於2023年7月27日公佈了Immunic（納斯達克股票代碼：IMUX）的最新目標股價。這家分析公司將目標股價定爲5.00美元，預計IMUX將在12個月內升至12個月內（可能上漲129.36％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Immunic (IMUX)?
分析師對Immunic（IMUX）的最新評級是多少？
The latest analyst rating for Immunic (NASDAQ: IMUX) was provided by Wedbush, and Immunic reiterated their outperform rating.
Immunic（納斯達克股票代碼：IMUX）的最新分析師評級由Wedbush提供，Immunic重申了其表現跑贏大盤的評級。
When is the next analyst rating going to be posted or updated for Immunic (IMUX)?
Immunic（IMUX）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immunic, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immunic was filed on July 27, 2023 so you should expect the next rating to be made available sometime around July 27, 2024.
分析師在進行了廣泛的研究（包括瀏覽公開財務報表、與Immunic的高管和客戶交談以及聽取財報電話會議）後得出股票評級。大多數分析師每三個月進行一次評級，因此每家公司每年應該獲得4個評級。Immunic的最後一次評級是在2023年7月27日提交的，因此您應該預計下一個評級將在2024年7月27日左右公佈。
Is the Analyst Rating Immunic (IMUX) correct?
分析師評級 Immunic (IMUX) 是否正確？
While ratings are subjective and will change, the latest Immunic (IMUX) rating was a reiterated with a price target of $0.00 to $5.00. The current price Immunic (IMUX) is trading at is $2.18, which is within the analyst's predicted range.
雖然評級是主觀的，會發生變化，但最新的Immunic（IMUX）評級得到了重申，目標股價爲0.00美元至5.00美元。Immunic（IMUX）目前的交易價格爲2.18美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。